跳至主要内容
临床试验/NCT01311349
NCT01311349已完成不适用

Evaluation of the Antimicrobial Activity In Vitro of Tigecycline in Comparison to Other Broad Spectrum Antibiotics in Isolates Collected From Patients

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 1,575 人开始时间: 2005年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,575

研究概览

简要总结

Various bacterial organisms will be tested in order to compile information regarding the effectiveness of tigecycline against certain bacteria seen in local communities.

详细描述

This is a prospective, microbiologic in vitro evaluation which will study the susceptibility of tigecycline in disk diffusion on clinical bacterial isolates collected from inpatients and outpatients. Fourteen hospital centers participated in the program. In vitro efficacy of tigecycline will be determined through the in vitro disk diffusion activity, using FDA breakpoints.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Any protocol-specified microorganism isolated from the samples collected from hospitalized patients and outpatients

排除标准

  • 未提供

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

相似试验

Study Evaluating Local Susceptibility Patterns... | 临床试验